Welcome to EQUITY DEVELOPMENT

The UK's longest established regulated provider of sponsored equity research.

We launched EQUITY DEVELOPMENT in 1997 becoming the first ever  regulated provider of Sponsored Equity Research in the UK.

Our research teams are made up of expert analysts with deep understanding & experience in their sectors.  Our research is distributed to all relevant investment classes & commentators. (at no cost to the reader).

We have made our name by specialising in those companies who are not receiving the attention that they merit, using detailed commentary, appropriate valuation metrics and regular publications to help eradicate undervaluation in the medium term.

 

FREE REGISTRATION

Sign up today and access the very latest company research

LOG IN

For access to all company research please

Lombard Medical Technologies Plc

Lombard Medical Technologies PLC (LMT) discovers, develops, assembles and markets innovative cardiovascular devices with a particular focus in the areas of stent-graft, stapling systems and polymer coatings for implantable medical devices.

Cash infusion

£1.4m (net) raised via Convertible Loan Notes

Talks ongoing regarding possible substantial investment from Middle East bank

Operational progress with international trials

Publication Date:
October 2 2008

Strong signals from the radar

Aorfix FDA trial recruitment on target 

Clinical evidence strengthening brand acceptance for all angulations

Refinancing required for commercialisation

Publication Date:
July 30 2008

Turning a corner

Raised £15m to fund commercialisation

Improved terms for Aorfix US trial approved by FDA

Loading and manufacturing problems now resolved – stock levels at all time high

Successful disposal of EndoArt

Publication Date:
March 26 2008

Interim results; strengthened and focused

US trials proceeding with 17 of 20 centres signed

Lombard's case strengthened for stents use in all aneurysms, not just >60°

Successful acquisition of Culzean Medical

Publication Date:
September 21 2007

Newsflow turns positive

Management redefining operational and financial strategies following turbulent 18 months

3 new research collaboration agreements in polymer coating division

Proposed changes to pivotal AAA trial accepted by FDA

Lombard Medical's share value seen in 28p-42p range (on differing risk factors) post financing

Publication Date:
July 24 2007

next